Amy Flaxman

Employment

• University of Oxford
• University of Oxford

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (20)

• Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults [version 2; peer review: 2 approved, 2 approved w…
  2026 DOI: 10.12688/wellcomeopenres.22900.2
  +Save
• Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol
  BMJ Open 2026 DOI: 10.1136/bmjopen-2025-107608
  +Save
• Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults
  Wellcome Open Research 2024 DOI: 10.12688/wellcomeopenres.22900.1
  +Save
• Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
  Clinical and Experimental Immunology 2023 DOI: 10.1093/cei/uxad013
  +Save
• Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
  Vaccines 2021 DOI: 10.3390/vaccines9080851
  +Save
• A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
  Nature Communications 2021 DOI: 10.1038/s41467-021-24906-y
  +Save
• Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
  Katie Ewer, Jordan R. Barrett, Sandra Belij‐Rammerstorfer +97 more
  Nature Medicine 2021 DOI: 10.1038/s41591-021-01363-0
  +Save
• Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
  Vaccines 2021 DOI: 10.3390/vaccines9030262
  +Save
• T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
  Katie Ewer, Jordan R. Barrett, Sandra Belij‐Rammerstorfer +97 more
  Nature Medicine 2021 DOI: 10.1038/s41591-020-01194-5
  +Save
• Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
  Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley +97 more
  Lancet (London, England) 2020 DOI: 10.1016/s0140-6736(20)31604-4
  +Save
• A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector
  Vaccines 2020 DOI: 10.3390/vaccines8020241
  +Save
• Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
  The Lancet. Infectious diseases 2020 DOI: 10.1016/S1473-3099(20)30160-2
  +Save
• Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line.
  Vaccines 2019 DOI: 10.3390/vaccines7010033
  +Save
• Heterogeneous early immune responses to the S. aureus EapH2 antigen induced by gastrointestinal tract colonisation impact the response to subsequent vaccination.
  Vaccine 2018 DOI: 10.1016/j.vaccine.2018.11.063
  +Save
• Vaccination with the Staphylococcus aureus secreted proteins EapH1 and EapH2 impacts both S. aureus carriage and invasive disease.
  Vaccine 2018 DOI: 10.1016/j.vaccine.2018.11.036
  +Save
• Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man
  Vaccines 2018 DOI: 10.3390/vaccines6030043
  +Save
• Development of persistent gastrointestinal S. aureus carriage in mice.
  Scientific reports 2017 DOI: 10.1038/s41598-017-12576-0
  +Save
• Risk factors for dermatitis in submariners during a submerged patrol: an observational cohort study
  BMJ Open 2016 DOI: 10.1136/bmjopen-2015-010975
  +Save
• Natural mutations in a Staphylococcus aureus virulence regulator attenuate cytotoxicity but permit bacteremia and abscess formation.
  2016 DOI: 10.1073/pnas.1520255113
  +Save
• Population variation in anti-S. aureus IgG isotypes influences surface protein A mediated immune subversion.
  2016 DOI: 10.1016/j.vaccine.2016.02.034
  +Save